MSF's Suerie Moon spoke in front of a US Senate Committee on promoting new treatments & cures for neglected diseases read more
NEW: The 13th Edition of Untangling the Web of Antiretroviral Price Reductions is now available download it here
VIDEO: MSF's community approach to treating malnutrition in Niger watch it here
WHO's work on the financing of medical research and development is given a fresh start read more
MSF Letter to GFATM on concerns over scale-up of AIDS treatment in light of Board of Directors Meeting read more
New European Parliament Working Group on Innovation & Access launches with support of Access Campaign read more
|
 |
|
 |
The MSF Access Campaign is calling for improved, cheaper and more suitable versions of existing vaccines, as well as development of new vaccines to address the needs of developing countries. The Campaign is seeking greater support for technology transfer and not-for-profit vaccine development.
|
In new report "Giving developing countries the best shot", MSF and Oxfam show how access to newer vaccines and the development of products for developing countries is faltering and failing to provide life-saving vaccines to children in developing countries. Read more |
MSF & Oxfam Consultation on Vaccines
In January 2010, MSF and Oxfam International met in Geneva, Switzerland to discuss how to improve access and stimulate vaccine development for development-poor settings.
|
In light of the GSK and Pfizer announcement that they signed a supply agreement for pneumococcal vaccines within GAVI’s advance market commitment (AMC) on 23 March 2010, MSF raises a number of concerns in fulfilling the needs of children in developing countries. Read more
|
|
Advance market commitments: The scheme to boost access to a life-saving vaccine has finally got its formal kick-off. But what does the pneumococcal vaccine AMC mean? Is it all it's cracked up to be? Will it work? And what happens now? Read more |
|
FIELD STORY Nearly 400,000 children and young adults have been vaccinated against meningococcal meningitis in Niger this April by MSF. The vaccine administered in this campaign will protect against three strains of meningitis for three years. Read more |
|
 |
|
 |
